Citadel Advisors
GLUE icon

Citadel Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Citadel Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Sell
8,800
-21,900
-71% -$414K ﹤0.01% 11928
2026
Q1 		$505K Buy
30,700
+12,000
+64% +$229K ﹤0.01% 9282
2025
Q4 		$293K Buy
18,700
+8,600
+85% +$116K ﹤0.01% 10208
2025
Q3 		$74.8K Sell
10,100
-34,400
-77% -$182K ﹤0.01% 12010
2025
Q2 		$201K Buy
44,500
+9,600
+28% +$42.8K ﹤0.01% 10676
2025
Q1 		$162K Sell
34,900
-25,700
-42% -$158K ﹤0.01% 10749
2024
Q4 		$421K Sell
60,600
-9,100
-13% -$68.3K ﹤0.01% 8945
2024
Q3 		$369K Buy
69,700
+58,000
+496% +$293K ﹤0.01% 8875
2024
Q2 		$43.8K Sell
11,700
-3,600
-24% -$18.4K ﹤0.01% 11912
2024
Q1 		$108K Sell
15,300
-28,500
-65% -$169K ﹤0.01% 11253
2023
Q4 		$247K Buy
43,800
+37,000
+544% +$145K ﹤0.01% 9541
2023
Q3 		$32.6K Sell
6,800
-35,200
-84% -$227K ﹤0.01% 12206
2023
Q2 		$288K Sell
42,000
-900
-2% -$5.82K ﹤0.01% 9137
2023
Q1 		$334K Buy
42,900
+24,300
+131% +$169K ﹤0.01% 9160
2022
Q4 		$142K Buy
+18,600
New +$155K ﹤0.01% 10694

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's GLUE Position: Q2 2026 in Review

Citadel Advisors reduced its Monte Rosa Therapeutics (GLUE) stake by 36% in Q2 2026, selling an estimated $1.72M and leaving 163,571 shares worth $3.96M. The position accounts for ﹤0.01% of the portfolio, ranked #5140.

Citadel Advisors first reported a position in GLUE in Q2 2021 and has held it in 20 quarters since. The position peaked at $7.79M in Q3 2022. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Citadel Advisors held 163,571 shares of Monte Rosa Therapeutics worth $3.96M as of Q2 2026.
  • Citadel Advisors sold 90,947 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5140 holding.
  • Citadel Advisors first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Citadel Advisors's Monte Rosa Therapeutics position peaked at $7.79M in Q3 2022.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.